Aucentra Therapeutics appoints Dr Tina Lavranos as Chief Business and Commercialisation Officer
Aucentra is very excited to welcome Dr Tina Lavranos to the Aucentra team!! Dr Lavranos has been appointed as Chief Business and Commercialisation Officer. Tina’s extensive experience in biotech and life sciences, her expertise in drug discovery and development of...
Aucentra Therapeutics appoints Dr David Fuller as Chief Medical Officer, commencing 16 November 2022
Aucentra Therapeutics is pleased to announce the appointment of Dr David Fuller as ‘Chief Medical Officer’ and a member of the executive management team commencing 16 November 2022. Dr Fuller will lead the company’s Australia and global clinical development at a...
Aucentra Therapeutics appoints Maria Maieli as Chief Financial Officer
Aucentra is very excited to announce our most recent addition to the growing team – Ms Maria Maieli, Chief Financial Officer. Maria is an accomplished executive with extensive experience in commercially driven industries having worked 30 years in a combination of...
Prof. Shudong Wang Gives Pancreatic Cancer Research Webinar for UniSA
ADELAIDE, Australia- 12 May 22 On 12th May 2022, Professor Shudong Wang, invited by the University of South Australia Dean of Research Clinical Health & Sciences, held a live webinar to discuss her ground-breaking pancreatic cancer research drug discovery and...
Aucentra Therapeutics Appoints Joe Bayer as Chief Executive Officer
ADELAIDE, Australia – 25/03/2022 Aucentra Therapeutics (https://www.aucentra.com/) is pleased to announce the appointment of Mr. Joe Bayer as Chief Executive Officer to lead the company in its growth and commercial phase. Aucentra Therapeutics is a clinical stage...
Aucentra initiates its Phase 1a/b study of Auceliciclib in Glioblastoma Multiforme (GBM) patients in combination with Temozolomide
24 February 2022 Adelaide, Australia- Aucentra Therapeutics is pleased to announce that it has received regulatory approval to progress to a Phase 1a/b clinical trial of Auceliciclib (AU3-14) in combination with Temozolomide for recurrent/refractory GBM patients....
John de Groot MD. Appointed to Scientific Advisory Board
Aucentra is thrilled to announce the appointment of John de Groot, MD, to our Scientific Advisory Board. Dr de Groot specializes in the treatment of patients with brain tumors, including glioblastomas and other gliomas. He is recognized for his expertise in...
Professor Chris Pepper Appointed to Scientific Advisory Board
Aucentra Therapeutics is delighted to announce the appointment of Professor Chris Pepper to our Scientific Advisory Board. Prof Chris Pepper is the Chair in Cancer Research at the Brighton and Sussex Medical School, UK. His research career has been extensive and...
Aucentra Receives Seed-Start Grant
Aucentra is excited to be awarded a seed-start grant of $700k by the South Australian government’s research and innovation fund. This funding will be used to test Aucentra’s leading drug candidate Auceliciclib. Auceliciclib, if successful in its clinical trials, will...
Auceliciclib as Pancreatic Cancer Treatment
Pancreatic cancer has only a five-year survival rate of less than ten per cent, but Aucentra Therapeutics is hoping to reverse this with a new investigational drug call AU3-14 (Auceliciclib). AU3-14 is taken as an oral capsule and demonstrating safety and therapeutic...